Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.
| Revenue (Most Recent Fiscal Year) | $4.91M |
| Net Income (Most Recent Fiscal Year) | $-53.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.60 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.19 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1906.22% |
| Net Margin (Trailing 12 Months) | -1079.94% |
| Return on Equity (Trailing 12 Months) | -143.15% |
| Return on Assets (Trailing 12 Months) | -101.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.32 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.23M |
| Free Float | 38.39M |
| Market Capitalization | $2.94M |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | 2.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |